Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
العنوان: | Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue |
---|---|
المؤلفون: | Dennis D. Weisenburger, Randy D. Gascoyne, Jan Delabie, Chih Jian Lih, Lisa M. Rimsza, Erlend B. Smeland, Elaine S. Jaffe, George E. Wright, Betty Glinsmann-Gibson, William D. Walsh, Louis M. Staudt, Andreas Rosenwald, German Ott, Kai Fu, Wing C. Chan, Joseph M. Connors, David W. Scott, Raymond R. Tubbs, P. Mickey Williams, Rita M. Braziel, James R. Cook, Anja Mottok, Elias Campo, Timothy C. Greiner |
المصدر: | Blood. 123:1214-1217 |
بيانات النشر: | American Society of Hematology, 2014. |
سنة النشر: | 2014 |
مصطلحات موضوعية: | Adult, Male, Pathology, medicine.medical_specialty, Adolescent, Biopsy, Concordance, Cell of origin, Immunology, Tissue Banks, Biology, Biochemistry, Fixatives, Young Adult, hemic and lymphatic diseases, Formaldehyde, Gene expression, medicine, Humans, Cell Lineage, Aged, Aged, 80 and over, Paraffin Embedding, medicine.diagnostic_test, Germinal center, Cell Biology, Hematology, Middle Aged, medicine.disease, LYMPHOID NEOPLASIA, Lymphoma, Gene Expression Regulation, Neoplastic, Leukemia, Female, Lymphoma, Large B-Cell, Diffuse, Transcriptome, Diffuse large B-cell lymphoma |
الوصف: | The assignment of diffuse large B-cell lymphoma into cell-of-origin (COO) groups is becoming increasingly important with the emergence of novel therapies that have selective biological activity in germinal center B cell–like or activated B cell–like groups. The Lymphoma/Leukemia Molecular Profiling Project's Lymph2Cx assay is a parsimonious digital gene expression (NanoString)–based test for COO assignment in formalin-fixed paraffin-embedded tissue (FFPET). The 20-gene assay was trained using 51 FFPET biopsies; the locked assay was then validated using an independent cohort of 68 FFPET biopsies. Comparisons were made with COO assignment using the original COO model on matched frozen tissue. In the validation cohort, the assay was accurate, with only 1 case with definitive COO being incorrectly assigned, and robust, with >95% concordance of COO assignment between 2 independent laboratories. These qualities, along with the rapid turnaround time, make Lymph2Cx attractive for implementation in clinical trials and, ultimately, patient management. |
تدمد: | 1528-0020 0006-4971 |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d202c011d429fe0641090cb0389025beTest https://doi.org/10.1182/blood-2013-11-536433Test |
حقوق: | OPEN |
رقم الانضمام: | edsair.doi.dedup.....d202c011d429fe0641090cb0389025be |
قاعدة البيانات: | OpenAIRE |
تدمد: | 15280020 00064971 |
---|